Patents Assigned to VIB VZW
  • Patent number: 11231416
    Abstract: This disclosure relates to a virus-like particle in which a small molecule-protein complex is entrapped, ensuring the formation of the small molecule-protein complex under physiological conditions, while protecting the small molecule-protein complex during purification and identification. The disclosure further relates to the use of such virus-like particle for the isolation and identification of small molecule-protein complexes.
    Type: Grant
    Filed: May 4, 2020
    Date of Patent: January 25, 2022
    Assignees: VIB VZW, Universiteit Gent
    Inventors: Jan Tavernier, Sven Eyckerman
  • Patent number: 11213815
    Abstract: The invention relates to a device and a method for growing and screening of plant samples, comprising a specialized multiwell plate system well-suited for housing granular media, for use in in vivo screening methods of uninterrupted plant tissue growth.
    Type: Grant
    Filed: August 17, 2017
    Date of Patent: January 4, 2022
    Assignees: VIB VZW, Universiteit Gent
    Inventors: Dirk Gustaaf Inzé, Stijn Dhondt
  • Patent number: 11208667
    Abstract: This disclosure relates to the field of secondary metabolite production in plants. More specifically, the disclosure relates to chimeric genes encoding a bHLH protein of subfamily Iva comprising a bHLH domain and their use in the regulation of biosynthesis and/or production of secondary metabolites in plants and plant-derived cell cultures.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: December 28, 2021
    Assignees: VIB VZW, Universiteit Gent, Universiteit Leiden
    Inventors: Alain Goossens, Jan Mertens, Alex Van Moerkercke, Jacob Pollier, Johan Memelink
  • Patent number: 11202795
    Abstract: This application relates to the field of neurodegenerative diseases, more particularly to the field of Parkinson's disease. In particular, the disclosure describes that inhibitors reducing FAS activity can be used for treatment of Parkinson's disease, in particular, the treatment of patients suffering from Parkinson's disease having loss of function mutations in PINK1 or PARKIN genes.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: December 21, 2021
    Assignees: VIB VZW, Katholieke Universiteit Leuven, KU Leuven R&E
    Inventors: Patrik Verstreken, Vanessa Morais Epifânio, Melissa Vos
  • Patent number: 11193136
    Abstract: The present invention relates to specific inhibitors of the cellulose synthase subunits 1 and 3 activity in plants, useful as a herbicide. In addition, the invention relates to mutant plants which are tolerant to the identified inhibitors. Specific mutant alleles of CESA1 and CESA3 genes can be used to obtain resistance in a plant when the inhibitors are used as herbicide.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: December 7, 2021
    Assignees: VIB VZW, UniversiteitGent
    Inventors: Lieven De Veylder, Rudy Vanderhaeghen, Zhubing Hu
  • Patent number: 11186807
    Abstract: The present invention relates to the field of fermentation, more particularly to ethanol production. Even more particularly the present invention relates to reduced aroma production during fermentation processes. The present invention provides mutant alleles and chimeric genes useful to develop yeast strains to limit acetate ester levels during fermentation. In addition, the invention also relates to the use of such yeast strains as well as of compounds for the production of fermented foods and liquids with reduced acetate ester levels.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: November 30, 2021
    Assignees: VIB VZW, Katholieke Universiteit Leuven, K.U. Leuven R&D
    Inventors: Kevin Verstrepen, Jan Steensels
  • Patent number: 11181527
    Abstract: The application discloses methods, kits and a novel biomarker to detect and/or to prognose inflammation in patients. The diagnostic test is based on measuring the ratio of galactosylated and non-galactosylated specific N-glycans as obtained by enzymatic treatment of the total mixture of proteins present in a body fluid such as blood, serum or plasma.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: November 23, 2021
    Assignees: VIB VZW, Universiteit Gent
    Inventors: Nico L. M. Callewaert, Dieter Vanderschaeghe, Tom Raes
  • Patent number: 11174497
    Abstract: The present application relates to the field of yeast and, specifically, to the identification of yeast alleles that are involved in maximal alcohol accumulation and/or in tolerance to high alcohol levels. Preferably, the alcohol is ethanol. The identified alleles can be combined or stacked with each other to construe and/or select high alcohol tolerant yeasts, most notably Saccharomyces species.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: November 16, 2021
    Assignees: VIB VZW, K.U. Leuven Research & Development
    Inventors: Kevin Verstrepen, Yudi Yang, Veerle Saels, Karin Voordeckers, Beatriz Herrera
  • Patent number: 11162954
    Abstract: The present invention relates to the field of GPCR structure biology and signaling. In particular, the present invention relates to protein binding domains directed against or capable of specifically binding to a functional conformational state of a G-protein-coupled receptor (GPCR). More specifically, the present invention provides protein binding domains that are capable of increasing the stability of a functional conformational state of a GPCR, in particular, increasing the stability of a GPCR in its active conformational state. The protein binding domains of the present invention can be used as a tool for the structural and functional characterization of G-protein-coupled receptors bound to various natural and synthetic ligands, as well as for screening and drug discovery efforts targeting GPCRs. Moreover, the invention also encompasses the diagnostic, prognostic and therapeutic usefulness of these protein binding domains for GPCR-related diseases.
    Type: Grant
    Filed: July 30, 2019
    Date of Patent: November 2, 2021
    Assignees: VIB VZW, Vrije Universiteit Brussel, Board of Trustees Leland Stanford Jr University
    Inventors: Jan Steyaert, Els Pardon, Soren G. F. Rasmussen, Juan Jose Fung, Brian Kobilka, Toon Laeremans
  • Patent number: 11162953
    Abstract: The present invention relates to the field of GPCR structure biology and signaling. In particular, the present invention relates to protein binding domains directed against or capable of specifically binding to a functional conformational state of a G-protein-coupled receptor (GPCR). More specifically, the present invention provides protein binding domains that are capable of increasing the stability of a functional conformational state of a GPCR, in particular, increasing the stability of a GPCR in its active conformational state. The protein binding domains of the present invention can be used as a tool for the structural and functional characterization of G-protein-coupled receptors bound to various natural and synthetic ligands, as well as for screening and drug discovery efforts targeting GPCRs. Moreover, the invention also encompasses the diagnostic, prognostic and therapeutic usefulness of these protein binding domains for GPCR-related diseases.
    Type: Grant
    Filed: July 30, 2019
    Date of Patent: November 2, 2021
    Assignees: VIB VZW, Vrije Universiteit Brussel, Board of Trustees of Leland Stanford Jr University
    Inventors: Jan Steyaert, Els Pardon, Soren G. F. Rasmussen, Juan Jose Fung, Brian Kobilka, Toon Laeremans
  • Patent number: 11155607
    Abstract: The present invention relates to polypeptides comprising an immunoglobulin variable domain, binding with high affinity to serum albumin for increasing the half-life of therapeutic agents and compositions, in particular for therapeutic agents comprising multispecific immunoglobulin variable domains. Also provided herein are methods for the production of polypeptides comprising serum albumin binding immunoglobulin variable domains of the present invention.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: October 26, 2021
    Assignee: VIB VZW
    Inventors: Gholamreza Hassanzadeh Ghassabeh, Steve Schoonooghe, Erik Depla
  • Publication number: 20210292376
    Abstract: The invention relates to mutant forms of CsgG. The invention also related to analyte detection and characterisation using CsgG.
    Type: Application
    Filed: March 8, 2021
    Publication date: September 23, 2021
    Applicants: Oxford Nanopore Technologies Ltd., VIB VZW, Vrije Universiteit Brussel
    Inventors: Stefan Howorka, Han Remaut, Lakmal Jayasinghe, Elizabeth Jayne Wallace, James Clarke, Richard George Hambley, Jonathan Bankes Pugh
  • Publication number: 20210284696
    Abstract: The present invention relates to novel protein pores and their uses in analyte detection and characterisation. The invention particularly relates to an isolated pore complex formed by a CsgG-like pore and a modified CsgF peptide, or a homologue or mutant thereof, thereby incorporating an additional channel constriction or reader head in the nanopore. The invention further relates to a transmembrane pore complex and methods for production of the pore complex and for use in molecular sensing and nucleic acid sequencing applications.
    Type: Application
    Filed: March 18, 2021
    Publication date: September 16, 2021
    Applicants: Oxford Nanopore Technologies Limited, VIB VZW, Vrije Universiteit Brussel
    Inventors: Han Remaut, Sander Van Der Verren, Nani Van Gerven, Lakmal Jayasinghe, Elizabeth Jayne Wallace, Pratik Raj Singh, Richard George Hambley, Michael Jordan, John Joseph Kilgour
  • Patent number: 11098337
    Abstract: The disclosure relates to the field of glyco-engineering, more specifically, to eukaryotic cells wherein both an endoglucosaminidase and a glycoprotein are present. These cells can be used to deglycosylate or partly deglycosylate the (exogenous) glycoprotein, in particular, without the need for adding an extra enzyme. Methods are also provided for the application of these cells in protein production. According to one specific aspect, the eukaryotic cells are glyco-engineered yeast cells in which, additionally, at least one exogenous enzyme needed for complex glycosylation is present, e.g., allowing easier separation of differentially glycosylated glycoproteins.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: August 24, 2021
    Assignees: VIB VZW, Universiteit Gent
    Inventors: Nico L. M. Callewaert, Karen De Pourcq, Steven Geysens, Leander Meuris
  • Patent number: 11098113
    Abstract: The present invention relates to immunoglobulin single variable domains that bind MIF and more in particular to polypeptides that comprise or essentially consist of one or more such immunoglobulin single variable domains; to nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: August 24, 2021
    Assignees: VIB VZW, Vrije Universiteit Brussel
    Inventors: Peter Vanlandschoot, Ines Cabrito, Benoît Stijlemans, Amanda Sparkes, Jo Van Ginderachter, Patrick De Baetselier
  • Patent number: 11084859
    Abstract: The present invention relates, in part, to chimeric proteins comprising mutant interferon-? and their use as therapeutic agents.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: August 10, 2021
    Assignees: Orionis Biosciences BV, VIB VZW, Universiteit Gent
    Inventors: Nikolai Kley, Jan Tavernier, Frank Peelman, Lennart Zabeau
  • Patent number: 11083751
    Abstract: The present application relates to tumor-associated dendritic cell (TADC) preparations and their use in treatment of tumor metastasis.
    Type: Grant
    Filed: February 22, 2017
    Date of Patent: August 10, 2021
    Assignees: VIB VZW, Vrije Universiteit Brussel, Universiteit Gent
    Inventors: Jo Van Ginderachter, Damya Laoui, Jiri Keirsse, Martin Guilliams
  • Patent number: 11072801
    Abstract: The present invention relates to nucleic acid regulatory elements that are able to enhance muscle-specific expression of genes, in particular expression in cardiac muscle and/or skeletal muscle, methods employing these regulatory elements and uses of these elements. Expression cassettes and vectors containing these nucleic acid regulatory elements are also disclosed. The present invention is particularly useful for applications using gene therapy, more particularly muscle-directed gene therapy, and for vaccination purposes.
    Type: Grant
    Filed: January 21, 2015
    Date of Patent: July 27, 2021
    Assignees: VRIJE Universiteit Brussel, VIB VZW, Universiteit Gent
    Inventors: Thierry Vandendriessche, Marinee Chuah, Pieter De Bleser
  • Patent number: RE48801
    Abstract: This disclosure relates to the field of cancer, particularly the field of melanoma. It was found that a particular long non-coding RNA (lncRNA) is specifically up-regulated in melanoma (but not other tumor) cells as compared to melanocytes. Inhibition of this lncRNA in melanoma cells leads to induction of apoptosis and is a novel therapeutic strategy in the treatment of melanoma.
    Type: Grant
    Filed: November 20, 2019
    Date of Patent: November 2, 2021
    Assignees: VIB VZW, Katholieke Universiteit Leuven, K.U. Leuven R&D, Universiteit Gent
    Inventors: Jean-Christophe Marine, Eleonora Leucci, Joke Vandesompele, Pieter Mestdagh
  • Patent number: RE48856
    Abstract: The application relates to the field of cancer, particularly to the field of solid tumors. It was found that a particular long non-coding RNA (lncRNA), NEAT1, an essential architectural component of nuclear paraspeckles, is required for the survival of cancer, but not that of normal, non-transformed, cells. Inhibition of NEAT1 reduces cell viability of cancer cells and induces apoptosis. These data identify NEAT1 as a novel therapeutic target for treatment of solid tumors.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: December 21, 2021
    Assignees: VIB VZW, Katholieke Universiteit Leuven, K.U.Leuven R&D
    Inventors: Jean-Christophe Marine, Laura Standaert